Latest Regulatory Risk News

Bio-Gene Technology Limited has announced an offer of over 95 million Placement Options to investors and its Lead Manager, contingent on shareholder approval at an upcoming extraordinary general meeting. If exercised, these options could inject approximately $3.8 million into the company.

Coda Minerals has submitted the Draft Scoping Report for its Elizabeth Creek Copper-Cobalt Project, marking a pivotal step in securing mining lease approvals in South Australia. This milestone reduces regulatory uncertainty and sets a clear path toward project development.

QMines Limited has announced a 16% increase in the gold resource at its Mount Mackenzie project, now totaling 151,000 ounces of gold and 902,000 ounces of silver. This upgrade strengthens the company’s regional production strategy and highlights potential for further resource growth.

Vulcan Energy has significantly expanded its lithium brine resource at Mannheim by 76% and reported its first geothermal energy resource estimate, marking a major step in its integrated renewable energy and lithium production strategy in Germany’s Upper Rhine Valley.

Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering shareholders discounted shares to fund the Phase 2 development of its targeted cancer therapy PTX-100.

Power Minerals Limited has launched a new options offer linked to a recent $1.3 million placement, alongside updates on key project acquisitions and divestments. The prospectus outlines significant risks and strategic directions as the company navigates growth and financial challenges.

Orpheus Uranium has launched a targeted exploration program at its Mt Douglas Project in the Northern Territory, supported by a government co-funding grant and approved permits enabling advanced drilling activities.

Green Critical Minerals’ McIntosh Graphite Project Pre-Feasibility Study confirms robust economics with a post-tax NPV of A$235 million and a 32.5-year mine life, underpinning plans for staged development and market entry.

The Takeovers Panel has declined to review its earlier decision on Keybridge Capital's board reshuffle, dismissing Yowie Group's challenge and signaling a firm stance on takeover conduct.

Adherium Limited has announced a partially underwritten entitlement offer aiming to raise approximately A$4.5 million through the issuance of new shares and options at a significant discount. The capital raise is designed to accelerate patient onboarding and product development for its respiratory monitoring technology.

The Takeovers Panel has declined to declare unacceptable circumstances in a dispute involving Mayfield Childcare Limited shareholders but has referred potential breaches of takeover laws to ASIC for further investigation.

Cleo Diagnostics has gained approval to access the prestigious PLCO biobank, a move set to strengthen its FDA submission and accelerate development of its ovarian cancer diagnostic tests.